{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:09:38Z","timestamp":1790388578673,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.3816\/clm.2006.n.039","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:46Z","timestamp":1221095446000},"page":"51-58","source":"Crossref","is-referenced-by-count":138,"title":["Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell Lymphoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshandra","family":"Talpur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin","family":"Apisarnthanarax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.039_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Investigation"},{"key":"10.3816\/CLM.2006.n.039_bib2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.039_bib3","first-page":"276","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"10.3816\/CLM.2006.n.039_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States: increasing incidence and description","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"10.3816\/CLM.2006.n.039_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0889-8588(18)30055-8","article-title":"Prognosis and staging of cutaneous T cell lymphoma","volume":"9","author":"Foss","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2006.n.039_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous Tcell lymphoma by skin stage: long term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","article-title":"Treatment of cutaneous T-cell lymphoma: current status and future directions","volume":"3","author":"Apisarnthanarax","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib9","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the Initials treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.039_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0733-8635(05)70155-8","article-title":"Emerging therapies in CTCL","volume":"18","author":"Duvic","year":"2000","journal-title":"Clin Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2","article-title":"DAB389IL2 diptheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma","volume":"58","author":"Duvic","year":"1998","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2006.n.039_bib12","first-page":"581","article-title":"Phase 2-3 clinical trial of oral targretin (bexarotene) capsules for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.039_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0190-9622(97)80148-X","article-title":"Response rates in photopheresis therapy for cutaneous T cell lymphoma. Response letter","volume":"37","author":"Duvic","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib15","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2006.n.039_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00001622-200409000-00002","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"16","author":"Foss","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2006.n.039_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"JAAD"},{"key":"10.3816\/CLM.2006.n.039_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.039_bib21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7326\/0003-4819-93-2-223","article-title":"Prospective staging evaluation of patients with cutaneous T-cell lymphomas","volume":"93","author":"Bunn","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2006.n.039_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T cell lymphoma by extracorporeal photchemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.039_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.1986.4.7.1094","article-title":"Combined modality treatment of cutaneous T-cell lymphoma: results of a 6-year follow-up","volume":"4","author":"Winkler","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.039_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Amer Acad Derm"},{"key":"10.3816\/CLM.2006.n.039_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000478-199206000-00002","article-title":"Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma","volume":"16","author":"Cerroni","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CLM.2006.n.039_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1987.5.2.208","article-title":"Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis","volume":"5","author":"Dmitrovsky","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of DAB389-IL2 (Ontak) for the treatment of cutaneous T cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib30","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of cutaneous T cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2006.n.039_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00001622-200111000-00015","article-title":"Gemcitabine in hematologic malignancies","volume":"13","author":"Nabhan","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib33","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2,\u20322\u2032-difluoro-2\u2032-deoxycytatidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2006.n.039_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.039_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0190-9622(98)70597-3","article-title":"Use of serum soluble interleukin-2 receptor levels to monitor patients with cutaneous T cell lymphoma","volume":"38","author":"Vonderheid","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.039_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1523-1747.ep12494223","article-title":"Soluble interleukin-2 receptors inhibit interleukin-2 dependent proliferation and cytotoxicity. Explanation for diminished natural killer cell activity in cutaneous T-cell lymphoma in vivo?","volume":"98","author":"Dummer","year":"1992","journal-title":"J Invest Dermatol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:48Z","timestamp":1588918188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1557919011702931"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.039","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}